Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Consensus Rating of “Buy” from Brokerages

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) have earned an average rating of “Buy” from the five research firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in the last year is $24.20.

Several research analysts have recently commented on the company. Wedbush reiterated an “outperform” rating and set a $23.00 price target on shares of Scholar Rock in a report on Tuesday, January 23rd. Truist Financial reiterated a “buy” rating and set a $20.00 price target on shares of Scholar Rock in a report on Monday. Piper Sandler restated an “overweight” rating and issued a $28.00 price objective on shares of Scholar Rock in a report on Tuesday. Raymond James began coverage on shares of Scholar Rock in a research report on Thursday. They issued a “strong-buy” rating and a $30.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Scholar Rock in a research report on Tuesday, March 19th.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, CFO Edward H. Myles sold 12,459 shares of the stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $18.83, for a total value of $234,602.97. Following the transaction, the chief financial officer now directly owns 168,784 shares in the company, valued at $3,178,202.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Scholar Rock news, CFO Edward H. Myles sold 12,459 shares of the stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $18.83, for a total value of $234,602.97. Following the transaction, the chief financial officer now directly owns 168,784 shares in the company, valued at $3,178,202.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mo Qatanani sold 2,512 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.74, for a total transaction of $39,538.88. Following the completion of the transaction, the insider now owns 147,019 shares in the company, valued at $2,314,079.06. The disclosure for this sale can be found here. Insiders have sold 46,303 shares of company stock worth $769,490 over the last three months. Insiders own 26.20% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Several large investors have recently modified their holdings of SRRK. Price T Rowe Associates Inc. MD boosted its holdings in shares of Scholar Rock by 47.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 8,436,185 shares of the company’s stock valued at $46,315,000 after acquiring an additional 2,704,442 shares during the period. Polar Capital Holdings Plc acquired a new stake in shares of Scholar Rock in the third quarter valued at approximately $10,664,000. BlackRock Inc. boosted its holdings in shares of Scholar Rock by 115.5% in the second quarter. BlackRock Inc. now owns 2,790,971 shares of the company’s stock valued at $21,044,000 after acquiring an additional 1,495,618 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Scholar Rock in the fourth quarter valued at approximately $21,275,000. Finally, Bank of America Corp DE boosted its holdings in shares of Scholar Rock by 2,187.0% in the fourth quarter. Bank of America Corp DE now owns 1,050,631 shares of the company’s stock valued at $9,508,000 after acquiring an additional 1,004,692 shares during the period. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Trading Up 3.0 %

Shares of SRRK stock opened at $15.45 on Thursday. The stock’s fifty day moving average is $15.55 and its two-hundred day moving average is $13.32. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.80 and a current ratio of 8.80. The firm has a market capitalization of $1.20 billion, a P/E ratio of -7.76 and a beta of 0.89. Scholar Rock has a fifty-two week low of $5.56 and a fifty-two week high of $21.17.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.